Alle Filter zurücksetzen
Kategorien
  • Pharma / Gesundheit
  • Pharmaindustrie / Medikamente
  • Hormone / Stoffwechsel
  • Filter zurücksetzen
Regionen/Länder
  • Europa
  • Deutschland
  • Frankreich
  • Italien
  • Spanien
  • Vereinigtes Königreich
  • Asien / Pazifik
  • China
  • Japan
  • Vietnam
  • Mittlerer Osten / Afrika
  • Nordamerika / USA
  • Australien
  • Mittel- / Südamerika
  • Filter zurücksetzen
Herausgeber
  • Datamonitor
  • Euromonitor
  • GBI Research
  • Global Markets Direct
  • GlobalData
  • Life Science Analytics
  • Technavio
  • Filter zurücksetzen
Sprache
  • Englisch
  • Filter zurücksetzen
Datum
  • 2013
  • 2012
  • 2011
  • 2010
  • 2009
  • 2008
  • Filter zurücksetzen
laedt
Ihre Vorteile:

versandkostenfreie Lieferung

i.d.R. sofortige Verfügbarkeit
aller Studien u. Marktanalysen

Bezahlung auf Rechnung
oder per Kreditkarte

Bestell- und Beratungshotline
© Vanessa - Fotolia.com

Gerne helfen wir Ihnen kostenfrei bei der Recherche nach Studien und Marktanalysen:

Tel.: +49 (0)221 788 748-11

Fax.: +49 (0)221 788 748-48

E-Mail: service[at]marktforschung.de

Werbung:

Studie Hormone / Stoffwechsel


Mit der Entscheidung für eine Veröffentlichung aus unserem Studien Shop zum Thema „Studie Hormone / Stoffwechsel“ erhalten Sie umfangreiche Fakten zur aktuellen Marktsituation. Sämtliche Marktanalysen stammen von renommierten Partnern aus der Marktforschung und enthalten Marktdaten und -prognosen. Wählen Sie aus unserer Übersicht einen Eintrag aus, um genauere Informationen zu der von Ihnen gewählten Marktanalyse Hormone / Stoffwechsel einzusehen.

Um noch treffsicherer die richtige Auswahl nationaler und internationaler Publikationen zum Themenbereich „Marktanalyse Hormone / Stoffwechsel“ zu erhalten nutzen Sie bitte unsere Such- und Filterfunktionen in der Seitenleiste. Gerne beraten wir Sie auch persönlich bei der Auswahl einer passenden Hormone / Stoffwechsel Studie an. Nutzen Sie dazu bitte unser Kontaktformular oder nehmen Sie telefonisch Kontakt zu uns auf.



Studien / Marktanalysen aus der Kategorie Hormone / Stoffwechsel

Titel Veröffentl. Preis netto *
3 / 2013 1.536,69 €

Growth Hormone Deficiency — Pipeline Review, H1 2013


Summary


Global Markets Direct’s, 'Growth Hormone Deficiency - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Growth Hormone Deficiency, complete with latest updates, and special features on late-stage and discontinued projects. It a... more mehr

2 / 2013 1.536,69 €

Chronic Kidney Disease (Chronic Renal Failure) — Pipeline Review, H1 2013


Summary


Global Markets Direct’s, 'Chronic Kidney Disease (Chronic Renal Failure) - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Chronic Kidney Disease (Chronic Renal Failure), complete with latest updates, and... more mehr

2 / 2013 1.536,69 €

Growth Disorders — Pipeline Review, H1 2013


Summary


Global Markets Direct’s, 'Growth Disorders - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Growth Disorders, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players inv... more mehr

2 / 2013 1.536,69 €

Kidney Fibrosis — Pipeline Review, H1 2013


Summary


Global Markets Direct’s, 'Kidney Fibrosis - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Kidney Fibrosis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involv... more mehr

2 / 2013 1.536,69 €

Urinary Incontinence — Pipeline Review, H1 2013


Summary


Global Markets Direct’s, 'Urinary Incontinence - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Urinary Incontinence, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key... more mehr

1 / 2013 1.536,69 €

TechNavio's analysts forecast the Global Endocrinology Drugs market to grow at a CAGR of 7.58 percent over the period 2012-2016. One of the key factors contributing to this market growth is the introduction of new drugs. The Global Endocrinology Drugs market has also been witnessing the increase in market consolidation. However, the off-label use of the human growth hormone could pose a challenge to the growth of this market.

more mehr

1 / 2013 1.920,86 €

Inguinal Hernia Global Clinical Trials Review, H1, 2013


Summary


GlobalData's clinical trial report, 'Inguinal Hernia Global Clinical Trials Review, H1, 2013' provides data on the Inguinal Hernia clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Inguinal Hernia. It includes an overview of the trial numbers and their recruitment status as per t... more mehr

12 / 2012 1.536,69 €

End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) — Pipeline Review, H2 2012


Summary


Global Markets Direct’s, 'End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Pipeline Review, H2 2012', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for End-Stage Kidney Disease (End-Stage Renal Disease or ESRD... more mehr

12 / 2012 1.536,69 €

Microalbuminuria — Pipeline Review, H2 2012


Summary


Global Markets Direct’s, 'Microalbuminuria - Pipeline Review, H2 2012', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Microalbuminuria, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players inv... more mehr

Nocturia – Pipeline Review, H2 2012

Von: Global Markets Direct
12 / 2012 1.536,69 €

Nocturia — Pipeline Review, H2 2012


Summary


Global Markets Direct’s, 'Nocturia - Pipeline Review, H2 2012', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Nocturia, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic... more mehr

11 / 2012 1.920,86 €

Focal Segmental Glomerulosclerosis (FSGS) Global Clinical Trials Review, H2, 2012


Summary


GlobalData's clinical trial report, 'Focal Segmental Glomerulosclerosis (FSGS) Global Clinical Trials Review, H2, 2012' provides data on the Focal Segmental Glomerulosclerosis (FSGS) clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Focal Segmental Glome... more mehr

11 / 2012 1.536,69 €

Hypoparathyroidism — Pipeline Review, H2 2012


Summary


Global Markets Direct’s, 'Hypoparathyroidism - Pipeline Review, H2 2012', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Hypoparathyroidism, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key playe... more mehr

Proteinuria – Pipeline Review, H2 2012

Von: Global Markets Direct
11 / 2012 1.536,69 €

Proteinuria — Pipeline Review, H2 2012


Summary


Global Markets Direct’s, 'Proteinuria - Pipeline Review, H2 2012', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Proteinuria, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the th... more mehr

11 / 2012 1.536,69 €

Thyroid Gland Disorders — Pipeline Review, H2 2012


Summary


Global Markets Direct’s, 'Thyroid Gland Disorders - Pipeline Review, H2 2012', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Thyroid Gland Disorders, complete with latest updates, and special features on late-stage and discontinued projects. It also re... more mehr

10 / 2012 1.536,69 €

Acute Renal Failure (ARF) (Acute Kidney Injury) — Pipeline Review, H2 2012


Summary


Global Markets Direct’s, 'Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline Review, H2 2012', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Acute Renal Failure (ARF) (Acute Kidney Injury), complete with latest updates, ... more mehr

10 / 2012 1.920,86 €

Hypothyroidism Global Clinical Trials Review, H2, 2012


Summary


GlobalData's clinical trial report, 'Hypothyroidism Global Clinical Trials Review, H2, 2012' provides data on the Hypothyroidism clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Hypothyroidism. It includes an overview of the trial numbers and their recruitment status as per the s... more mehr

10 / 2012 1.536,69 €

Interstitial Cystitis (Painful Bladder Syndrome) — Pipeline Review, H2 2012


Summary


Global Markets Direct’s, 'Interstitial Cystitis (Painful Bladder Syndrome) - Pipeline Review, H2 2012', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Interstitial Cystitis (Painful Bladder Syndrome), complete with latest update... more mehr

10 / 2012 1.536,69 €

Other Genito Urinary Disorders — Pipeline Review, H2 2012


Summary


Global Markets Direct’s, 'Other Genito Urinary Disorders - Pipeline Review, H2 2012', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Other Genito Urinary Disorders, complete with latest updates, and special features on late-stage and discontinued... more mehr

10 / 2012 1.920,86 €

Urinary Retention Global Clinical Trials Review, H2, 2012


Summary


GlobalData's clinical trial report, 'Urinary Retention Global Clinical Trials Review, H2, 2012' provides data on the Urinary Retention clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Urinary Retention. It includes an overview of the trial numbers and their recruitment status ... more mehr

9 / 2012 1.536,69 €

Focal Segmental Glomerulosclerosis (FSGS) — Pipeline Review, H2 2012


Summary


Global Markets Direct’s, 'Focal Segmental Glomerulosclerosis (FSGS) - Pipeline Review, H2 2012', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Focal Segmental Glomerulosclerosis (FSGS), complete with latest updates, and special featur... more mehr

9 / 2012 1.536,69 €

Glomerulonephritis — Pipeline Review, H2 2012


Summary


Global Markets Direct’s, 'Glomerulonephritis - Pipeline Review, H2 2012', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Glomerulonephritis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key playe... more mehr

9 / 2012 1.920,86 €

Interstitial Cystitis (Painful Bladder Syndrome) Global Clinical Trials Review, H2, 2012


Summary


GlobalData's clinical trial report, 'Interstitial Cystitis (Painful Bladder Syndrome) Global Clinical Trials Review, H2, 2012' provides data on the Interstitial Cystitis (Painful Bladder Syndrome) clinical trial scenario. This report provides elemental information and data relating to the clinical trials on ... more mehr

9 / 2012 1.536,69 €

Overactive Bladder — Pipeline Review, H2 2012


Summary


Global Markets Direct’s, 'Overactive Bladder - Pipeline Review, H2 2012', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Overactive Bladder, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key playe... more mehr

9 / 2012 1.536,69 €

Polycystic Kidney Disease — Pipeline Review, H2 2012


Summary


Global Markets Direct’s, 'Polycystic Kidney Disease - Pipeline Review, H2 2012', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Polycystic Kidney Disease, complete with latest updates, and special features on late-stage and discontinued projects. It a... more mehr

Renal Failure – Pipeline Review, H2 2012

Von: Global Markets Direct
9 / 2012 1.536,69 €

Renal Failure — Pipeline Review, H2 2012


Summary


Global Markets Direct’s, 'Renal Failure - Pipeline Review, H2 2012', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Renal Failure, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in ... more mehr

8 / 2012 1.920,86 €

Bacteriuria Global Clinical Trials Review, H2, 2012


Summary


GlobalData's clinical trial report, 'Bacteriuria Global Clinical Trials Review, H2, 2012' provides data on the Bacteriuria clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Bacteriuria. It includes an overview of the trial numbers and their recruitment status as per the site of trial... more mehr

8 / 2012 1.536,69 €

Chronic Kidney Disease (Chronic Renal Failure) — Pipeline Review, H2 2012


Summary


Global Markets Direct’s, 'Chronic Kidney Disease (Chronic Renal Failure) - Pipeline Review, H2 2012', provides an overview of the Chronic Kidney Disease (Chronic Renal Failure) therapeutic pipeline. This report provides information on the therapeutic development for Chronic Kidney Disease (Chronic Renal Failure), c... more mehr

8 / 2012 1.536,69 €

Growth Disorders — Pipeline Review, H2 2012


Summary


Global Markets Direct’s, 'Growth Disorders - Pipeline Review, H2 2012', provides an overview of the Growth Disorders therapeutic pipeline. This report provides information on the therapeutic development for Growth Disorders, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players i... more mehr

Kidney Disease – Pipeline Review, H2 2012

Von: Global Markets Direct
8 / 2012 1.536,69 €

Kidney Disease — Pipeline Review, H2 2012


Summary


Global Markets Direct’s, 'Kidney Disease - Pipeline Review, H2 2012', provides an overview of the Kidney Disease therapeutic pipeline. This report provides information on the therapeutic development for Kidney Disease, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved ... more mehr

8 / 2012 1.536,69 €

Kidney Fibrosis — Pipeline Review, H2 2012


Summary


Global Markets Direct’s, 'Kidney Fibrosis - Pipeline Review, H2 2012', provides an overview of the Kidney Fibrosis therapeutic pipeline. This report provides information on the therapeutic development for Kidney Fibrosis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players invol... more mehr

8 / 2012 1.536,69 €

Urinary Incontinence — Pipeline Review, H2 2012


Summary


Global Markets Direct’s, 'Urinary Incontinence - Pipeline Review, H2 2012', provides an overview of the Urinary Incontinence therapeutic pipeline. This report provides information on the therapeutic development for Urinary Incontinence, complete with latest updates, and special features on late-stage and discontinued projects. It also revie... more mehr

6 / 2012 1.920,86 €

Acute Renal Failure (ARF) (Acute Kidney Injury) Global Clinical Trials Review, H1, 2012


Summary


GlobalData's clinical trial report, 'Acute Renal Failure (ARF) (Acute Kidney Injury) Global Clinical Trials Review, H1, 2012' provides data on the Acute Renal Failure (ARF) (Acute Kidney Injury)/Impaired Glucose Toleranceclinical trial scenario. This report provides elemental information and data relating to ... more mehr

6 / 2012 384,17 €

Microalbuminuria — Pipeline Review, H1 2012


Summary


Global Markets Direct’s, 'Microalbuminuria - Pipeline Review, H1 2012', provides an overview of the Microalbuminuria therapeutic pipeline. This report provides information on the therapeutic development for Microalbuminuria, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players i... more mehr

6 / 2012 1.920,86 €

Other Metabolic Disorders Global Clinical Trials Review, H1, 2012


Summary


GlobalData's clinical trial report, 'Other Metabolic Disorders Global Clinical Trials Review, H1, 2012' provides data on the Other Metabolic Disorders clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Other Metabolic Disorders. It includes an overview of the trial numbe... more mehr

6 / 2012 1.920,86 €

Pre-Diabetes/Impaired Glucose Tolerance Global Clinical Trials Review, H1, 2012


Summary


GlobalData's clinical trial report, ' Global Clinical Trials Review, H1, 2012' provides data on the Pre-Diabetes/Impaired Glucose Toleranceclinical trial scenario. This report provides elemental information and data relating to the clinical trials on Pre-Diabetes/Impaired Glucose Tolerance. It includes an overview of... more mehr

5 / 2012 384,17 €

Congenital Adrenal Hyperplasia (Adrenogenital Syndrome) — Pipeline Review, H1 2012


Summary


Global Markets Direct’s, 'Congenital Adrenal Hyperplasia (Adrenogenital Syndrome) - Pipeline Review, H1 2012', provides an overview of the Congenital Adrenal Hyperplasia (Adrenogenital Syndrome) therapeutic pipeline. This report provides information on the therapeutic development for Congenital Adrenal Hyp... more mehr

5 / 2012 768,34 €

Diabetic Gastroparesis Global Clinical Trials Review, H1, 2012


Summary


GlobalData's clinical trial report, 'Diabetic Gastroparesis Global Clinical Trials Review, H1, 2012' provides data on the Diabetic Gastroparesis clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Diabetic Gastroparesis . It includes an overview of the trial numbers and thei... more mehr

5 / 2012 768,34 €

Gestational Diabetes Global Clinical Trials Review, H1, 2012


Summary


GlobalData's clinical trial report, 'Gestational Diabetes Global Clinical Trials Review, H1, 2012' provides data on the Gestational Diabetes clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Gestational Diabetes. It includes an overview of the trial numbers and their recruit... more mehr

5 / 2012 384,17 €

Hypoparathyroidism — Pipeline Review, H1 2012


Summary


Global Markets Direct’s, 'Hypoparathyroidism - Pipeline Review, H1 2012', provides an overview of the Hypoparathyroidism therapeutic pipeline. This report provides information on the therapeutic development for Hypoparathyroidism, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key p... more mehr

5 / 2012 768,34 €

Lupus Nephritis Global Clinical Trials Review, H1, 2012


Summary


GlobalData's clinical trial report, 'Lupus Nephritis Global Clinical Trials Review, H1, 2012' provides data on the Lupus Nephritis clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Lupus Nephritis . It includes an overview of the trial numbers and their recruitment status as per ... more mehr

Proteinuria – Pipeline Review, H1 2012

Von: Global Markets Direct
5 / 2012 384,17 €

Proteinuria — Pipeline Review, H1 2012


Summary


Global Markets Direct’s, 'Proteinuria - Pipeline Review, H1 2012', provides an overview of the Proteinuria therapeutic pipeline. This report provides information on the therapeutic development for Proteinuria, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the thera... more mehr

5 / 2012 384,17 €

Thyroid Gland Disorders — Pipeline Review, H1 2012


Summary


Global Markets Direct’s, 'Thyroid Gland Disorders - Pipeline Review, H1 2012', provides an overview of the Thyroid Gland Disorders therapeutic pipeline. This report provides information on the therapeutic development for Thyroid Gland Disorders, complete with latest updates, and special features on late-stage and discontinued projects. I... more mehr

4 / 2012 384,17 €

Acute Renal Failure (ARF) (Acute Kidney Injury) — Pipeline Review, H1 2012


Summary


Global Markets Direct’s, 'Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline Review, H1 2012', provides an overview of the Acute Renal Failure (ARF) (Acute Kidney Injury) therapeutic pipeline. This report provides information on the therapeutic development for Acute Renal Failure (ARF) (Acute Kidney Injury... more mehr

4 / 2012 384,17 €

Cushing's Syndrome — Pipeline Review, H1 2012


Summary


Global Markets Direct’s, 'Cushing's Syndrome - Pipeline Review, H1 2012', provides an overview of the Cushing's Syndrome therapeutic pipeline. This report provides information on the therapeutic development for Cushing's Syndrome, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key p... more mehr

4 / 2012 768,34 €

Growth Hormone Deficiency Global Clinical Trials Review, H1, 2012


Summary


GlobalData's clinical trial report, 'Growth Hormone Deficiency Global Clinical Trials Review, H1, 2012' provides data on the Growth Hormone Deficiency clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Growth Hormone Deficiency. It includes an overview of the trial numbe... more mehr

4 / 2012 384,17 €

Interstitial Cystitis (Painful Bladder Syndrome) — Pipeline Review, H1 2012


Summary


Global Markets Direct’s, 'Interstitial Cystitis (Painful Bladder Syndrome) - Pipeline Review, H1 2012', provides an overview of the Interstitial Cystitis (Painful Bladder Syndrome) therapeutic pipeline. This report provides information on the therapeutic development for Interstitial Cystitis (Painful Bladder Synd... more mehr

Nocturia – Pipeline Review, H1 2012

Von: Global Markets Direct
4 / 2012 384,17 €

Nocturia — Pipeline Review, H1 2012


Summary


Global Markets Direct’s, 'Nocturia - Pipeline Review, H1 2012', provides an overview of the Nocturia therapeutic pipeline. This report provides information on the therapeutic development for Nocturia, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic devel... more mehr

Acromegaly – Pipeline Review, H1 2012

Von: Global Markets Direct
3 / 2012 384,17 €

Acromegaly — Pipeline Review, H1 2012


Summary


Global Markets Direct’s, 'Acromegaly - Pipeline Review, H1 2012', provides an overview of the Acromegaly therapeutic pipeline. This report provides information on the therapeutic development for Acromegaly, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeut... more mehr

3 / 2012 2.689,20 €

Endocrinology Market to 2018 - Advanced Injection Devices for Growth Hormone and Somatostatin will Improve Ease of Use for Patients


Summary


GBI Research, the leading business intelligence provider, has released its latest research 'Endocrinology Market to 2018-Advanced Injection Devices for Growth Hormone and Somatostatin will Improve Ease of Use for Patients”, which provides insights into the endocri... more mehr

3 / 2012 384,17 €

Focal Segmental Glomerulosclerosis (FSGS) — Pipeline Review, H1 2012


Summary


Global Markets Direct’s, 'Focal Segmental Glomerulosclerosis (FSGS) - Pipeline Review, H1 2012', provides an overview of the Focal Segmental Glomerulosclerosis (FSGS) therapeutic pipeline. This report provides information on the therapeutic development for Focal Segmental Glomerulosclerosis (FSGS), complete with latest ... more mehr

3 / 2012 384,17 €

Glomerulonephritis — Pipeline Review, H1 2012


Summary


Global Markets Direct’s, 'Glomerulonephritis - Pipeline Review, H1 2012', provides an overview of the Glomerulonephritis therapeutic pipeline. This report provides information on the therapeutic development for Glomerulonephritis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key p... more mehr

3 / 2012 384,17 €

Growth Hormone Deficiency — Pipeline Review, H1 2012


Summary


Global Markets Direct’s, 'Growth Hormone Deficiency - Pipeline Review, H1 2012', provides an overview of the Growth Hormone Deficiency therapeutic pipeline. This report provides information on the therapeutic development for Growth Hormone Deficiency, complete with latest updates, and special features on late-stage and discontinued pro... more mehr

Hyperoxaluria – Pipeline Review, H1 2012

Von: Global Markets Direct
3 / 2012 384,17 €

Hyperoxaluria — Pipeline Review, H1 2012


Summary


Global Markets Direct’s, 'Hyperoxaluria - Pipeline Review, H1 2012', provides an overview of the Hyperoxaluria therapeutic pipeline. This report provides information on the therapeutic development for Hyperoxaluria, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in t... more mehr

3 / 2012 384,17 €

Hyperparathyroidism — Pipeline Review, H1 2012


Summary


Global Markets Direct’s, 'Hyperparathyroidism - Pipeline Review, H1 2012', provides an overview of the Hyperparathyroidism therapeutic pipeline. This report provides information on the therapeutic development for Hyperparathyroidism, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews k... more mehr

3 / 2012 384,17 €

Lupus Nephritis — Pipeline Review, H1 2012


Summary


Global Markets Direct’s, 'Lupus Nephritis - Pipeline Review, H1 2012', provides an overview of the Lupus Nephritis therapeutic pipeline. This report provides information on the therapeutic development for Lupus Nephritis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players invol... more mehr

3 / 2012 384,17 €

Overactive Bladder — Pipeline Review, H1 2012


Summary


Global Markets Direct’s, 'Overactive Bladder - Pipeline Review, H1 2012', provides an overview of the Overactive Bladder therapeutic pipeline. This report provides information on the therapeutic development for Overactive Bladder, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key p... more mehr

3 / 2012 384,17 €

Polycystic Kidney Disease — Pipeline Review, H1 2012


Summary


Global Markets Direct’s, 'Polycystic Kidney Disease - Pipeline Review, H1 2012', provides an overview of the Polycystic Kidney Disease therapeutic pipeline. This report provides information on the therapeutic development for Polycystic Kidney Disease, complete with latest updates, and special features on late-stage and discontinued pro... more mehr

2 / 2012 384,17 €

Growth Disorders — Pipeline Review, H1 2012


Summary


Global Markets Direct’s, 'Growth Disorders - Pipeline Review, H1 2012', provides an overview of the Growth Disorders therapeutic pipeline. This report provides information on the therapeutic development for Growth Disorders, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players i... more mehr

2 / 2012 768,34 €

Male Hypogonadism Global Clinical Trials Review, H1, 2012

Summary

GlobalData's clinical trial report, 'Male Hypogonadism Global Clinical Trials Review, H1, 2012' provides data on the Male Hypogonadism clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Male Hypogonadism. It includes an overview of the trial numbers and their recruitment status as per the s... more mehr

1 / 2012 3.069,54 €

Growth Hormone Deficiency (GHD) Therapeutics - Pipeline Assessment and Market Forecasts to 2018

Summary

GlobalData, the industry analysis specialist, has released its new report, 'Growth Hormone Deficiency (GHD) Therapeutics - Pipeline Assessment and Market Forecasts to 2018”. The report is an essential source of information and analysis on the global Growth Hormone Deficiency (GHD) Therapeutics market. The repor... more mehr

1 / 2012 768,34 €

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Global Clinical Trials Review, H1, 2012

Summary

GlobalData's clinical trial report, 'Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Global Clinical Trials Review, H1, 2012' provides data on the Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer clinical trial scenario. This r... more mehr

11 / 2011 2.305,03 €

Bacteriuria Global Clinical Trials Review, H2, 2011

Summary

GlobalData's clinical trial report, 'Bacteriuria Global Clinical Trials Review, H2, 2011' provides data on the Bacteriuria clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Bacteriuria. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction ... more mehr

11 / 2011 768,34 €

Chronic Kidney Disease (Chronic Renal Failure) Global Clinical Trials Review, H2, 2011

Summary

GlobalData's clinical trial report, 'Chronic Kidney Disease (Chronic Renal Failure) Global Clinical Trials Review, H2, 2011' provides data on the Chronic Kidney Disease (Chronic Renal Failure) clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Chronic Kidney Dis... more mehr

11 / 2011 384,17 €

Congenital Adrenal Hyperplasia (Adrenogenital Syndrome) - Pipeline Review, H2 2011

Summary

Global Markets Direct’s, 'Congenital Adrenal Hyperplasia (Adrenogenital Syndrome) - Pipeline Review, H2 2011', provides an overview of the Congenital Adrenal Hyperplasia (Adrenogenital Syndrome) therapeutic pipeline. This report provides information on the therapeutic development for Congenital Adrenal Hyperplasia (Adrenoge... more mehr

11 / 2011 1.536,69 €

Focal Segmental Glomerulosclerosis (FSGS) Global Clinical Trials Review, H2, 2011

Summary

GlobalData's clinical trial report, 'Focal Segmental Glomerulosclerosis (FSGS) Global Clinical Trials Review, H2, 2011' provides data on the Focal Segmental Glomerulosclerosis (FSGS) clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Focal Segmental Glomerulosclerosi... more mehr

11 / 2011 2.689,20 €

Growth Hormone Deficiency (GHD) Therapeutics - Pipeline Assessment and Market Forecasts to 2018

Summary

GlobalData, the Industry analysis specialist, has released its new report, 'Growth Hormone Deficiency (GHD) Therapeutics - Pipeline Assessment and Market Forecasts to 2018”. The report is an essential source of information on the global growth hormone deficiency therapeutics market, and provides analysis of a n... more mehr

11 / 2011 384,17 €

Hypoparathyroidism - Pipeline Review, H2 2011

Summary

Global Markets Direct’s, 'Hypoparathyroidism - Pipeline Review, H2 2011', provides an overview of the Hypoparathyroidism therapeutic pipeline. This report provides information on the therapeutic development for Hypoparathyroidism, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in... more mehr

11 / 2011 768,34 €

Interstitial Cystitis Global Clinical Trials Review, H2, 2011

Summary

GlobalData's clinical trial report, 'Interstitial Cystitis Global Clinical Trials Review, H2, 2011' provides data on the Interstitial Cystitis clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Interstitial Cystitis. It includes an overview of the trial numbers and their recruitment sta... more mehr

Proteinuria - Pipeline Review, H2 2011

Von: Global Markets Direct
11 / 2011 384,17 €

Proteinuria - Pipeline Review, H2 2011

Summary

Global Markets Direct’s, 'Proteinuria - Pipeline Review, H2 2011', provides an overview of the Proteinuria therapeutic pipeline. This report provides information on the therapeutic development for Proteinuria, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development... more mehr

11 / 2011 384,17 €

Thyroid Gland Disorders - Pipeline Review, H2 2011

Summary

Global Markets Direct’s, 'Thyroid Gland Disorders - Pipeline Review, H2 2011', provides an overview of the Thyroid Gland Disorders therapeutic pipeline. This report provides information on the therapeutic development for Thyroid Gland Disorders, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key... more mehr

11 / 2011 768,34 €

Urinary Retention Global Clinical Trials Review, H2, 2011

Summary

GlobalData's clinical trial report, 'Urinary Retention Global Clinical Trials Review, H2, 2011' provides data on the Urinary Retention clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Urinary Retention. It includes an overview of the trial numbers and their recruitment status as per the s... more mehr

Acromegaly - Pipeline Review, H2 2011

Von: Global Markets Direct
10 / 2011 384,17 €

Acromegaly - Pipeline Review, H2 2011

Summary

Global Markets Direct’s, 'Acromegaly - Pipeline Review, H2 2011', provides an overview of the Acromegaly therapeutic pipeline. This report provides information on the therapeutic development for Acromegaly, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for... more mehr

10 / 2011 8.067,61 €

Benign Prostatic Hyperplasia (BPH) Therapeutics - Pipeline Assessment and Market Forecasts to 2018

Summary

GlobalData, the industry analysis specialist, has released its new report, 'Benign Prostatic Hyperplasia (BPH) Therapeutics - Pipeline Assessment and Market Forecasts to 2018”. The report is an essential source of information and analysis on the global BPH market. The report identifies the key trends shaping... more mehr

10 / 2011 384,17 €

Focal Segmental Glomerulosclerosis (FSGS) - Pipeline Review, H2 2011

Summary

Global Markets Direct’s, 'Focal Segmental Glomerulosclerosis (FSGS) - Pipeline Review, H2 2011', provides an overview of the Focal Segmental Glomerulosclerosis (FSGS) therapeutic pipeline. This report provides information on the therapeutic development for Focal Segmental Glomerulosclerosis (FSGS), complete with latest updates, and speci... more mehr

10 / 2011 384,17 €

Glomerulonephritis - Pipeline Review, H2 2011

Summary

Global Markets Direct’s, 'Glomerulonephritis - Pipeline Review, H2 2011', provides an overview of the Glomerulonephritis therapeutic pipeline. This report provides information on the therapeutic development for Glomerulonephritis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in... more mehr

10 / 2011 384,17 €

Growth Hormone Deficiency - Pipeline Review, H2 2011

Summary

Global Markets Direct’s, 'Growth Hormone Deficiency - Pipeline Review, H2 2011', provides an overview of the Growth Hormone Deficiency therapeutic pipeline. This report provides information on the therapeutic development for Growth Hormone Deficiency, complete with latest updates, and special features on late-stage and discontinued projects. It also rev... more mehr

10 / 2011 768,34 €

Growth Hormone Deficiency Global Clinical Trials Review, H2 2011

Summary

GlobalData's clinical trial report, 'Growth Hormone Deficiency Global Clinical Trials Review, H2, 2011' provides data on the Growth Hormone Deficiency clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Growth Hormone Deficiency. It includes an overview of the trial numbers and their ... more mehr

Hyperoxaluria - Pipeline Review, H2 2011

Von: Global Markets Direct
10 / 2011 384,17 €

Hyperoxaluria - Pipeline Review, H2 2011

Summary

Global Markets Direct’s, 'Hyperoxaluria - Pipeline Review, H2 2011', provides an overview of the Hyperoxaluria therapeutic pipeline. This report provides information on the therapeutic development for Hyperoxaluria, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic dev... more mehr

10 / 2011 384,17 €

Hyperparathyroidism - Pipeline Review, H2 2011

Summary

Global Markets Direct’s, 'Hyperparathyroidism - Pipeline Review, H2 2011', provides an overview of the Hyperparathyroidism therapeutic pipeline. This report provides information on the therapeutic development for Hyperparathyroidism, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involve... more mehr

Lupus Nephritis - Pipeline Review, H2 2011

Von: Global Markets Direct
10 / 2011 384,17 €

Lupus Nephritis - Pipeline Review, H2 2011

Summary

Global Markets Direct’s, 'Lupus Nephritis - Pipeline Review, H2 2011', provides an overview of the Lupus Nephritis therapeutic pipeline. This report provides information on the therapeutic development for Lupus Nephritis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therape... more mehr

10 / 2011 384,17 €

Overactive Bladder - Pipeline Review, H2 2011

Summary

Global Markets Direct’s, 'Overactive Bladder - Pipeline Review, H2 2011', provides an overview of the Overactive Bladder therapeutic pipeline. This report provides information on the therapeutic development for Overactive Bladder, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in... more mehr

10 / 2011 384,17 €

Polycystic Kidney Disease - Pipeline Review, H2 2011

Summary

Global Markets Direct’s, 'Polycystic Kidney Disease - Pipeline Review, H2 2011', provides an overview of the Polycystic Kidney Disease therapeutic pipeline. This report provides information on the therapeutic development for Polycystic Kidney Disease, complete with latest updates, and special features on late-stage and discontinued projects. It also rev... more mehr

Growth Disorders - Pipeline Review, H2 2011

Von: Global Markets Direct
9 / 2011 384,17 €

Growth Disorders - Pipeline Review, H2 2011

Summary

Global Markets Direct’s, 'Growth Disorders - Pipeline Review, H2 2011', provides an overview of the Growth Disorders therapeutic pipeline. This report provides information on the therapeutic development for Growth Disorders, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the the... more mehr

9 / 2011 384,17 €

Male Hypogonadism - Pipeline Review, H2 2011

Summary

Global Markets Direct’s, 'Male Hypogonadism - Pipeline Review, H2 2011', provides an overview of the Male Hypogonadism therapeutic pipeline. This report provides information on the therapeutic development for Male Hypogonadism, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the... more mehr

9 / 2011 2.689,20 €

Post-Menopausal Hormone Replacement Therapy (HRT) - Pipeline Assessment and Market Forecasts to 2018

Summary

GlobalData, the industry analysis specialist, has released its new report, 'Post-Menopausal Hormone Replacement Therapy (HRT) - Pipeline Assessment and Market Forecasts to 2018”. The report is an essential source of information and analysis on the global Post-Menopausal Hormone Replacement Therapy (HRT) ma... more mehr

8 / 2011 384,17 €

Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline Review, H2 2011

Summary

Global Markets Direct’s, 'Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline Review, H2 2011', provides an overview of the Acute Renal Failure (ARF) (Acute Kidney Injury) therapeutic pipeline. This report provides information on the therapeutic development for Acute Renal Failure (ARF) (Acute Kidney Injury), complete with l... more mehr

8 / 2011 768,34 €

Benign Prostatic Hyperplasia Global Clinical Trials Review, H2, 2011

Summary

GlobalData's clinical trial report, 'Benign Prostatic Hyperplasia Global Clinical Trials Review, H2, 2011' provides data on the Benign Prostatic Hyperplasia clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Benign Prostatic Hyperplasia. It includes an overview of the trial numbe... more mehr

8 / 2011 384,17 €

Cushing's Syndrome - Pipeline Review, H2 2011

Summary

Global Markets Direct’s, 'Cushing's Syndrome - Pipeline Review, H2 2011', provides an overview of the Cushing's Syndrome therapeutic pipeline. This report provides information on the therapeutic development for Cushing's Syndrome, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in... more mehr

8 / 2011 768,34 €

Hypothyroidism Global Clinical Trials Review, H2, 2011

Summary

GlobalData's clinical trial report, 'Hypothyroidism Global Clinical Trials Review, H2, 2011' provides data on the Hypothyroidism clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Hypothyroidism. It includes an overview of the trial numbers and their recruitment status as per the site of trial... more mehr

8 / 2011 384,17 €

Interstitial Cystitis - Pipeline Review, H2 2011

Summary

Global Markets Direct’s, 'Interstitial Cystitis - Pipeline Review, H2 2011', provides an overview of the Interstitial Cystitis therapeutic pipeline. This report provides information on the therapeutic development for Interstitial Cystitis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players... more mehr

Nocturia - Pipeline Review, H2 2011

Von: Global Markets Direct
8 / 2011 384,17 €

Nocturia - Pipeline Review, H2 2011

Summary

Global Markets Direct’s, 'Nocturia - Pipeline Review, H2 2011', provides an overview of the Nocturia therapeutic pipeline. This report provides information on the therapeutic development for Nocturia, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Nocturi... more mehr

6 / 2011 768,34 €

Growth Hormone Deficiency Global Clinical Trials Review, Q2, 2011

Summary

GlobalData's clinical trial report, 'Growth Hormone Deficiency Global Clinical Trials Review, Q2, 2011' provides data on the Growth Hormone Deficiency clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Growth Hormone Deficiency. It includes an overview of the trial numbers and their... more mehr

6 / 2011 768,34 €

Hyperparathyroidism Global Clinical Trials Review, Q2, 2011

Summary

GlobalData's clinical trial report, 'Hyperparathyroidism Global Clinical Trials Review, Q2, 2011' provides data on the Hyperparathyroidism clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Hyperparathyroidism. It includes an overview of the trial numbers and their recruitment status as p... more mehr

6 / 2011 768,34 €

Hypothyroidism Global Clinical Trials Review, Q2, 2011

Summary

GlobalData's clinical trial report, 'Hypothyroidism Global Clinical Trials Review, Q2, 2011' provides data on the Hypothyroidism clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Hypothyroidism. It includes an overview of the trial numbers and their recruitment status as per the site of trial... more mehr

5 / 2011 384,17 €

Congenital Adrenal Hyperplasia - Pipeline Review, Q2 2011

Summary

Global Markets Direct’s, 'Congenital Adrenal Hyperplasia - Pipeline Review, Q2 2011', provides an overview of the Congenital Adrenal Hyperplasia therapeutic pipeline. This report provides information on the therapeutic development for Congenital Adrenal Hyperplasia, complete with latest updates, and special features on late-stage and discontinued p... more mehr

5 / 2011 384,17 €

Hypoparathyroidism - Pipeline Review, Q2 2011

Summary

Global Markets Direct’s, 'Hypoparathyroidism - Pipeline Review, Q2 2011', provides an overview of the Hypoparathyroidism therapeutic pipeline. This report provides information on the therapeutic development for Hypoparathyroidism, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in... more mehr

Proteinuria - Pipeline Review, Q2 2011

Von: Global Markets Direct
5 / 2011 384,17 €

Proteinuria - Pipeline Review, Q2 2011

Summary

Global Markets Direct’s, 'Proteinuria - Pipeline Review, Q2 2011', provides an overview of the Proteinuria therapeutic pipeline. This report provides information on the therapeutic development for Proteinuria, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development... more mehr

5 / 2011 384,17 €

Thyroid Gland Disorders - Pipeline Review, Q2 2011

Summary

Global Markets Direct’s, 'Thyroid Gland Disorders - Pipeline Review, Q2 2011', provides an overview of the Thyroid Gland Disorders therapeutic pipeline. This report provides information on the therapeutic development for Thyroid Gland Disorders, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key... more mehr

4 / 2011 384,17 €

Acute Renal Failure (ARF) - Pipeline Review, Q2 2011

Summary

Global Markets Direct’s, 'Acute Renal Failure (ARF) - Pipeline Review, Q2 2011', provides an overview of the Acute Renal Failure (ARF) therapeutic pipeline. This report provides information on the therapeutic development for Acute Renal Failure (ARF), complete with latest updates, and special features on late-stage and discontinued projects. It also rev... more mehr

4 / 2011 384,17 €

Cushing's Syndrome - Pipeline Review, Q2 2011

Summary

Global Markets Direct’s, 'Cushing's Syndrome - Pipeline Review, Q2 2011', provides an overview of the Cushing's Syndrome therapeutic pipeline. This report provides information on the therapeutic development for Cushing's Syndrome, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in... more mehr

4 / 2011 2.689,20 €

Gout Therapeutics Market to 2017- Entry of Novel Therapies such as Krystexxa, Uloric, Adenuric and Colcrys to Drive Market

Summary

GBI Research has released its pharmaceutical research, 'Gout Therapeutics Market to 2017 - Entry of Novel Therapies such as Krystexxa, Uloric, Adenuric and Colcrys to Drive Market”, which provides insights into gout therapeutics sales and price forecasts until 2017. The report also de... more mehr

4 / 2011 384,17 €

Interstitial Cystitis - Pipeline Review, Q2 2011

Summary

Global Markets Direct’s, 'Interstitial Cystitis - Pipeline Review, Q2 2011', provides an overview of the Interstitial Cystitis therapeutic pipeline. This report provides information on the therapeutic development for Interstitial Cystitis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players... more mehr

Nocturia - Pipeline Review, Q2 2011

Von: Global Markets Direct
4 / 2011 384,17 €

Nocturia - Pipeline Review, Q2 2011

Summary

Global Markets Direct’s, 'Nocturia - Pipeline Review, Q2 2011', provides an overview of the Nocturia therapeutic pipeline. This report provides information on the therapeutic development for Nocturia, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Nocturi... more mehr

3 / 2011 384,17 €

Acromegaly And Gigantism (Growth Hormone Disorders) - Pipeline Review, Q1 2011

Summary

Global Markets Direct’s, 'Acromegaly And Gigantism (Growth Hormone Disorders) - Pipeline Review, Q1 2011', provides an overview of the Acromegaly And Gigantism (Growth Hormone Disorders) therapeutic pipeline. This report provides information on the therapeutic development for Acromegaly And Gigantism (Growth Hormone Disorders),... more mehr

3 / 2011 384,17 €

Focal Segmental Glomerulosclerosis (FSGS) - Pipeline Review, Q1 2011

Summary

Global Markets Direct’s, 'Focal Segmental Glomerulosclerosis (FSGS) - Pipeline Review, Q1 2011', provides an overview of the Focal Segmental Glomerulosclerosis (FSGS) therapeutic pipeline. This report provides information on the therapeutic development for Focal Segmental Glomerulosclerosis (FSGS), complete with latest updates, and speci... more mehr

3 / 2011 384,17 €

Glomerulonephritis - Pipeline Review, Q1 2011

Summary

Global Markets Direct’s, 'Glomerulonephritis - Pipeline Review, Q1 2011', provides an overview of the Glomerulonephritis therapeutic pipeline. This report provides information on the therapeutic development for Glomerulonephritis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in... more mehr

3 / 2011 3.073,38 €

Glomerulonephritis Therapeutics - Pipeline Assessment and Market Forecasts to 2017

Summary

GlobalData, the industry analysis specialist, has released its new report, 'Glomerulonephritis Therapeutics - Pipeline Assessment and Market Forecasts to 2017”. The report is an essential source of information and analysis on the global glomerulonephritis therapeutics market. The report identifies the key trends shaping and... more mehr

3 / 2011 384,17 €

Growth Hormone Deficiency - Pipeline Review, Q1 2011

Summary

Global Markets Direct’s, 'Growth Hormone Deficiency - Pipeline Review, Q1 2011', provides an overview of the Growth Hormone Deficiency therapeutic pipeline. This report provides information on the therapeutic development for Growth Hormone Deficiency, complete with latest updates, and special features on late-stage and discontinued projects. It also rev... more mehr

Hyperoxaluria - Pipeline Review, Q1 2011

Von: Global Markets Direct
3 / 2011 384,17 €

Hyperoxaluria - Pipeline Review, Q1 2011

Summary

Global Markets Direct’s, 'Hyperoxaluria - Pipeline Review, Q1 2011', provides an overview of the Hyperoxaluria therapeutic pipeline. This report provides information on the therapeutic development for Hyperoxaluria, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic dev... more mehr

3 / 2011 384,17 €

Hyperparathyroidism - Pipeline Review, Q1 2011

Summary

Global Markets Direct’s, 'Hyperparathyroidism - Pipeline Review, Q1 2011', provides an overview of the Hyperparathyroidism therapeutic pipeline. This report provides information on the therapeutic development for Hyperparathyroidism, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involve... more mehr

Lupus Nephritis - Pipeline Review, Q1 2011

Von: Global Markets Direct
3 / 2011 384,17 €

Lupus Nephritis - Pipeline Review, Q1 2011

Summary

Global Markets Direct’s, 'Lupus Nephritis - Pipeline Review, Q1 2011', provides an overview of the Lupus Nephritis therapeutic pipeline. This report provides information on the therapeutic development for Lupus Nephritis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therape... more mehr

3 / 2011 768,34 €

Lupus Nephritis Global Clinical Trials Review, Q1, 2011

Summary

GlobalData's clinical trial report, 'Lupus Nephritis Global Clinical Trials Review, Q1, 2011' provides data on the Lupus Nephritis clinical trial scenario. This report provides in-depth information and data relating to the clinical trials on Lupus Nephritis . It includes an overview of the trial numbers and their recruitment status as per the site of ... more mehr

3 / 2011 384,17 €

Overactive Bladder - Pipeline Review, Q1 2011

Summary

Global Markets Direct’s, 'Overactive Bladder - Pipeline Review, Q1 2011', provides an overview of the Overactive Bladder therapeutic pipeline. This report provides information on the therapeutic development for Overactive Bladder, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in... more mehr

3 / 2011 384,17 €

Polycystic Kidney Disease - Pipeline Review, Q1 2011

Summary

Global Markets Direct’s, 'Polycystic Kidney Disease - Pipeline Review, Q1 2011', provides an overview of the Polycystic Kidney Disease therapeutic pipeline. This report provides information on the therapeutic development for Polycystic Kidney Disease, complete with latest updates, and special features on late-stage and discontinued projects. It also rev... more mehr

2 / 2011 384,17 €

Benign Prostatic Hyperplasia - Pipeline Review, Q1 2011

Summary

Global Markets Direct’s, 'Benign Prostatic Hyperplasia - Pipeline Review, Q1 2011', provides an overview of the Benign Prostatic Hyperplasia therapeutic pipeline. This report provides information on the therapeutic development for Benign Prostatic Hyperplasia, complete with latest updates, and special features on late-stage and discontinued projects.... more mehr

Calming and Sleeping - China

Von: Euromonitor
2 / 2011 675,00 €

The market for calming and sleeping products experienced moderate growth during 2010, with year-on-year growth of just over 7%. The rising number of elderly people in China has driven demand for these kinds of products. However, since many health food products also claim to provide similar functions to calming and sleeping products in China, the OTC market for such products has come under considerable pressure and therefore registered o... more mehr

2 / 2011 384,17 €

Chronic Kidney Disease (Chronic Renal Failure) - Pipeline Review, Q1 2011

Summary

Global Markets Direct’s, 'Chronic Kidney Disease (Chronic Renal Failure) - Pipeline Review, Q1 2011', provides an overview of the Chronic Kidney Disease (Chronic Renal Failure) therapeutic pipeline. This report provides information on the therapeutic development for Chronic Kidney Disease (Chronic Renal Failure), complete with lates... more mehr

2 / 2011 768,34 €

Diabetes Global Clinical Trials Review, Q1, 2011

Summary

GlobalData's clinical trial report, 'Diabetes Global Clinical Trials Review, Q1, 2011' provides data on the Diabetes clinical trial scenario. This report provides in-depth information and data relating to the clinical trials on Diabetes. It includes an overview of the trial numbers and their recruitment status as per the site of trial development throughout ... more mehr

2 / 2011 768,34 €

Diabetic Foot Infection (DFI) Global Clinical Trials Review, Q1, 2011

Summary

GlobalData's clinical trial report, 'Diabetic Foot Infection (DFI) Global Clinical Trials Review, Q1, 2011' provides data on the Diabetic Foot Infection (DFI) Global clinical trial scenario. This report provides in-depth information and data relating to the clinical trials on Diabetic Foot Infection (DFI) . It includes an overview of the... more mehr

2 / 2011 768,34 €

Diabetic Foot Ulcers Global Clinical Trials Review, Q1, 2011

Summary

GlobalData's clinical trial report, 'Diabetic Foot Ulcers Global Clinical Trials Review, Q1, 2011' provides data on the Diabetic Foot Ulcers clinical trial scenario. This report provides in-depth information and data relating to the clinical trials on Diabetic Foot Ulcers . It includes an overview of the trial numbers and their recruitment status ... more mehr

2 / 2011 768,34 €

Diabetic Gastroparesis Global Clinical Trials Review, Q1, 2011

Summary

GlobalData's clinical trial report, 'Diabetic Gastroparesis Global Clinical Trials Review, Q1, 2011' provides data on the Diabetic Gastroparesis Global clinical trial scenario. This report provides in-depth information and data relating to the clinical trials on Diabetic Gastroparesis . It includes an overview of the trial numbers and their rec... more mehr

2 / 2011 768,34 €

Diabetic Ketoacidosis Global Clinical Trials Review, Q1, 2011

Summary

GlobalData's clinical trial report, 'Diabetic Ketoacidosis Global Clinical Trials Review, Q1, 2011' provides data on the Diabetic Ketoacidosis Global clinical trial scenario. This report provides in-depth information and data relating to the clinical trials on Diabetic Ketoacidosis. It includes an overview of the trial numbers and their recruitm... more mehr

2 / 2011 768,34 €

Gestational Diabetes Global Clinical Trials Review, Q1, 2011

Summary

GlobalData's clinical trial report, 'Gestational Diabetes Global Clinical Trials Review, Q1, 2011' provides data on the Gestational Diabetes Global clinical trial scenario. This report provides in-depth information and data relating to the clinical trials on Gestational Diabetes . It includes an overview of the trial numbers and their recruitment... more mehr

2 / 2011 768,34 €

Glucose Intolerance Global Clinical Trials Review, Q1, 2011

Summary

GlobalData's clinical trial report, 'Glucose Intolerance Global Clinical Trials Review, Q1, 2011' provides data on the Glucose Intolerance Global clinical trial scenario. This report provides in-depth information and data relating to the clinical trials on Glucose Intolerance. It includes an overview of the trial numbers and their recruitment stat... more mehr

Growth Disorders - Pipeline Review, Q1 2011

Von: Global Markets Direct
2 / 2011 384,17 €

Growth Disorders - Pipeline Review, Q1 2011

Summary

Global Markets Direct’s, 'Growth Disorders - Pipeline Review, Q1 2011', provides an overview of the Growth Disorders therapeutic pipeline. This report provides information on the therapeutic development for Growth Disorders, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the the... more mehr

2 / 2011 768,34 €

Hyperglycemia Global Clinical Trials Review, Q1, 2011

Summary

GlobalData's clinical trial report, 'Hyperglycemia Global Clinical Trials Review, Q1, 2011' provides data on the Hyperglycemia Global clinical trial scenario. This report provides in-depth information and data relating to the clinical trials on Hyperglycemia . It includes an overview of the trial numbers and their recruitment status as per the site of t... more mehr

2 / 2011 768,34 €

Hypoglycemia Global Clinical Trials Review, Q1, 2011

Summary

GlobalData's clinical trial report, 'Hypoglycemia Global Clinical Trials Review, Q1, 2011' provides data on the Hypoglycemia Global clinical trial scenario. This report provides in-depth information and data relating to the clinical trials on Hypoglycemia . It includes an overview of the trial numbers and their recruitment status as per the site of trial... more mehr

2 / 2011 768,34 €

Obesity Global Clinical Trials Review, Q1, 2011

Summary

GlobalData's clinical trial report, 'Obesity Global Clinical Trials Review, Q1, 2011' provides data on the obesity clinical trial scenario. This report provides in-depth information and data relating to the clinical trials on obesity . It includes an overview of the trial numbers and their recruitment status as per the site of trial development throughout the... more mehr

2 / 2011 384,17 €

Urinary Incontinence - Pipeline Review, Q1 2011

Summary

Global Markets Direct’s, 'Urinary Incontinence - Pipeline Review, Q1 2011', provides an overview of the Urinary Incontinence therapeutic pipeline. This report provides information on the therapeutic development for Urinary Incontinence, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players inv... more mehr

11 / 2010 1.536,69 €

Growth Hormone Deficiency (GHD) - Pipeline Assessment and Market Forecasts to 2017

Summary

GlobalData’s report, 'Growth Hormone Deficiency - Pipeline Assessment and Market Forecasts to 2017”, is an essential source of information and analysis on the global groeth hormone deficiency (GHD) market. The report identifies the key trends shaping and driving the global GHD market. The report also provides insights int... more mehr

9 / 2010 11.678,83 €

Introduction

Sales of hormone replacement therapies treating menopausal symptoms have seen a sharp decline in recent years as a result of safety concerns raised by the Women's Health Initiative (WHI) study in 2002. Coupling this with Pfizer's acquisition of Wyeth, the leading estrogen manufacturer, the future direction of the market is uncertain.

Reasons to Purchase

* Understand the current and futur... more mehr

9 / 2010 11.678,83 €

Introduction

Sales of hormone replacement therapies treating menopausal symptoms have seen a sharp decline in recent years as a result of safety concerns raised by the Women's Health Initiative (WHI) study in 2002. Coupling this with Pfizer's acquisition of Wyeth, the leading estrogen manufacturer, the future direction of the market is uncertain.

Reasons to Purchase

* Understand the current and futur... more mehr

9 / 2010 11.678,83 €

Introduction

Sales of hormone replacement therapies treating menopausal symptoms have seen a sharp decline in recent years as a result of safety concerns raised by the Women's Health Initiative (WHI) study in 2002. Coupling this with Pfizer's acquisition of Wyeth, the leading estrogen manufacturer, the future direction of the market is uncertain.
Scope

* Patient potential analysis across the seven major ma... more mehr

9 / 2010 11.678,83 €

Introduction

Sales of hormone replacement therapies treating menopausal symptoms have seen a sharp decline in recent years as a result of safety concerns raised by the Women's Health Initiative (WHI) study in 2002. Coupling this with Pfizer's acquisition of Wyeth, the leading estrogen manufacturer, the future direction of the market is uncertain.
Scope

* Patient potential analysis across the seven major ma... more mehr

9 / 2010 11.678,83 €

Introduction

The testosterone replacement therapy market grew with an impressive compound annual growth rate [CAGR]: 24.3% from 2005 to 2009 to reach $838m sales. While these drugs can reverse the symptoms of testosterone deficiency rather efficaciously, only an estimated 5% of affected people receive treatment.
Scope

* Patient potential analysis across the seven major markets
* Review of the key ... more mehr

9 / 2010 11.678,83 €

Introduction

The testosterone replacement therapy market grew with an impressive compound annual growth rate [CAGR]: 24.3% from 2005 to 2009 to reach $838m sales. While these drugs can reverse the symptoms of testosterone deficiency rather efficaciously, only an estimated 5% of affected people receive treatment.
Scope

* Patient potential analysis across the seven major markets
* Review of the key ... more mehr

9 / 2010 11.678,83 €

Introduction

The testosterone replacement therapy market grew with an impressive compound annual growth rate [CAGR]: 24.3% from 2005 to 2009 to reach $838m sales. While these drugs can reverse the symptoms of testosterone deficiency rather efficaciously, only an estimated 5% of affected people receive treatment.

Reasons to Purchase

* Understand the current and future market size and dynamics
... more mehr

9 / 2010 11.678,83 €

Introduction

The testosterone replacement therapy market grew with an impressive compound annual growth rate [CAGR]: 24.3% from 2005 to 2009 to reach $838m sales. While these drugs can reverse the symptoms of testosterone deficiency rather efficaciously, only an estimated 5% of affected people receive treatment.

Reasons to Purchase

* Understand the current and future market size and dynamics
... more mehr

8 / 2010 1.536,69 €

Hormone Replacement Therapy in Menopause - Pipeline Assessment and Market Forecasts to 2017

Summary

GlobalData's has released its pharmaceutical and healthcare report, 'Hormone Replacement Therapy in Menopause - Pipeline Assessment and Market Forecasts to 2017”. The report is an essential source of information and analysis on the global menopause hormone therapy market. The report identifies the key trends shapin... more mehr

5 / 2010 675,00 €

The number of people migrating to large cities like Hanoi, Danang, and Ho Chi Minh City continued to increase during 2009 and urban noise and air pollution is becoming and ever larger problem in Vietnam. Moreover, the population density in large cities such as Ho Chi Minh City is very high, causing traffic jams and high levels of smoke and dirt which are causing throat, lung, and nose related health problems.

Euromonitor Inte... more mehr

5 / 2010 1.536,69 €

Growth Hormone Deficiency (GHD) - Pipeline Analysis and Market Forecasts to 2016

Summary

GlobalData, the industry analysis specialist’s new report, 'Growth Hormone Deficiency (GHD) - Pipeline Analysis and Market Forecasts to 2016” is an essential source of information and analysis on the global growth hormone deficiency market. The report identifies the key trends shaping and driving the global growth hormone d... more mehr

4 / 2010 1.148,67 €

Life Science Analytics', Growth Hormone Deficiency Therapy Area Pipeline Report contains detailed information on the growth hormone deficiency drug pipeline. This report provides insight into the pipeline status of growth hormone deficiency drugs by company and by stage as well as a summary of the latest news and developments in this area.

Scope of the report:

Each Life Science Analytics’ Therapy Area Pipeline Re... more mehr

4 / 2010 1.148,67 €

Life Science Analytics', Hormone Replacement Therapy Therapy Area Pipeline Report contains detailed information on the hormone replacement therapy drug pipeline. This report provides insight into the pipeline status of hormone replacement therapy drugs by company and by stage as well as a summary of the latest news and developments in this area.

Scope of the report:

Each Life Science Analytics’ Therapy Area Pipel... more mehr

Hyperthyroidism Therapy Area Pipeline Report

Von: Life Science Analytics
4 / 2010 1.148,67 €

Life Science Analytics', Hyperthyroidism Therapy Area Pipeline Report contains detailed information on the hyperthyroidism drug pipeline. This report provides insight into the pipeline status of hyperthyroidism drugs by company and by stage as well as a summary of the latest news and developments in this area.

Scope of the report:

Each Life Science Analytics’ Therapy Area Pipeline Report provides the user with re... more mehr

Hypogonadism Therapy Area Pipeline Report

Von: Life Science Analytics
4 / 2010 1.148,67 €

Life Science Analytics', Hypogonadism Therapy Area Pipeline Report contains detailed information on the hypogonadism drug pipeline. This report provides insight into the pipeline status of hypogonadism drugs by company and by stage as well as a summary of the latest news and developments in this area.

Scope of the report:

Each Life Science Analytics’ Therapy Area Pipeline Report provides the user with real detail... more mehr

10 / 2009 11.678,83 €

Introduction

Since the 1960s, hormonal contraceptives have been widely used as effective birth control in the developed world. Although they are mainly used to prevent pregnancies, they can be used for treating other conditions such as acne, endometriosis, and polycystic ovarian syndrome. In 2008, the hormonal contraceptives market was worth $6.2 billion across the seven major pharmaceutical countries.

Reasons to P... more mehr

4 / 2008 1.148,67 €

Life Science Analytics', 'Metabolic Endocrinology Growth Hormone Deficiency ' contains detailed information on the current drug pipeline. This report provides insight into the pipeline status of allergy drugs by company and by stage as well as a summary of the latest news and developments in this area.

Scope of the report:

Each Life Science Analytics’ Therapy Area Pipeline Report provides the user with real deta... more mehr

4 / 2008 1.148,67 €

Life Science Analytics', 'Metabolic Endocrinology Hormone Replacement Therapy ' contains detailed information on the current drug pipeline. This report provides insight into the pipeline status of allergy drugs by company and by stage as well as a summary of the latest news and developments in this area.

Scope of the report:

Each Life Science Analytics’ Therapy Area Pipeline Report provides the user with real de... more mehr

Metabolic Endocrinology Hypercalcemia

Von: Life Science Analytics
4 / 2008 1.148,67 €

Life Science Analytics', 'Metabolic Endocrinology Hypercalcemia ' contains detailed information on the current drug pipeline. This report provides insight into the pipeline status of allergy drugs by company and by stage as well as a summary of the latest news and developments in this area.

Scope of the report:

Each Life Science Analytics’ Therapy Area Pipeline Report provides the user with real detail on drug p... more mehr

Metabolic Endocrinology Hypocalcemia

Von: Life Science Analytics
4 / 2008 1.148,67 €

Life Science Analytics', 'Metabolic Endocrinology Hypocalcemia ' contains detailed information on the current drug pipeline. This report provides insight into the pipeline status of allergy drugs by company and by stage as well as a summary of the latest news and developments in this area.

Scope of the report:

Each Life Science Analytics’ Therapy Area Pipeline Report provides the user with real detail on drug pi... more mehr

Metabolic Endocrinology Hypogonadism

Von: Life Science Analytics
4 / 2008 1.148,67 €

Life Science Analytics', 'Metabolic Endocrinology Hypogonadism ' contains detailed information on the current drug pipeline. This report provides insight into the pipeline status of allergy drugs by company and by stage as well as a summary of the latest news and developments in this area.

Scope of the report:

Each Life Science Analytics’ Therapy Area Pipeline Report provides the user with real detail on drug pi... more mehr


Eine Bestellung kann online oder per Fax erfolgen. Haben Sie sich für eine Marktanalyse Hormone / Stoffwechsel entschieden, stellen wir Ihnen diese schnellstmöglich per eMail zur Verfügung. Wenn Sie Interesse daran haben regelmäßig aktuelle Informationen, Daten und Analysen aus dem Bereich „Studie Hormone / Stoffwechsel“ zu erhalten nutzen Sie eines unserer zahlreichen Angebote, zum Beispiel unsere Research-Flatrate.


*Unser Angebot richtet sich an gewerbliche Kunden, daher sind alle Preise netto ausgewiesen.

In Abhngigkeit von Ihrer Rechnungsanschrift ist hierauf noch USt. zu entrichten (Deutschland z.Z. 19%).

Der korrekte Gesamtendpreis wird Ihnen nach Angabe Ihrer Rechnungsadresse im weiteren Bestellablauf ausgewiesen.

Für Sie protokollierte Studien / Marktanalysen: